Efficacy, safety, and current applications of brimonidine
Authors:
- Scott J FudembergSFScott J Fudemberg
- Corey BatisteCBCorey Batiste
- L Jay KatzLKL Jay Katz
- 4 November 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 7 (6) , 795-799
Abstract
Background: The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan® P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan®, Allergan) evolved the marketing and application of this therapy. Objective: We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management. Results/conclusion: Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.Keywords
This publication has 16 references indexed in Scilit:
- Unintentional Ingestion of Brimonidine Antiglaucoma DropsPediatric Emergency Care, 2007
- Ocular Comfort of Combination Glaucoma Therapies: Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide 2%/Timolol 0.5%Journal of Ocular Pharmacology and Therapeutics, 2007
- Drug-Induced EctropionOphthalmology, 2007
- Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucomaBritish Journal of Ophthalmology, 2006
- Side-Effect Profile of Brimonidine Tartrate in ChildrenOphthalmology, 2005
- Duplicate publicationAmerican Journal of Health-System Pharmacy, 2005
- Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular HypertensionJournal of Ocular Pharmacology and Therapeutics, 2005
- Pharmacological Therapy for GlaucomaDrugs, 2000
- Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapyOphthalmology, 1999
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patientsAmerican Journal of Ophthalmology, 1999